Latest news
REPL Upgraded by Wedbush -- Price Target Raised to $19.00 - GuruFocusGuruFocus · Fri, 07 Aug 2026 19:32:14 GMTReplimune price target raised to $20 from $16 at BMO Capital - tipranks.comtipranks.com · Fri, 07 Aug 2026 15:53:51 GMTWedbush Upgrades Replimune (REPL) on FDA Approval, Price Target Raised to $19 - GuruFocusGuruFocus · Fri, 07 Aug 2026 11:58:00 GMTLeerink Partners Upgrades Replimune Group to Outperform From Market Perform, Adjusts Price Target to $17 From $11 - marketscreener.commarketscreener.com · Tue, 04 Aug 2026 12:08:07 GMTWedbush Upgrades Replimune Group to Outperform From Neutral, Raises Price Target to $12 From $9 - MoomooMoomoo · Fri, 31 Jul 2026 07:00:00 GMT